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Numerous studies support the role for mutations in
the phosphatase and tensin homologue (PTEN) tu-
mor suppressor gene and unopposed estrogen stim-
ulation in the pathogenesis of uterine endometrioid
carcinoma. However, the relation between PTEN sig-
naling and estrogen/estrogen receptor in endome-
trial tumorigenesis remains unresolved. We used ge-
netically engineered mice as a model to address this
relation. Mice with a single deleted Pten allele
(Pten/) spontaneously develop complex atypical
hyperplasia and 20% develop endometrial cancer.
To determine the effect of removing endogenous es-
trogen, we performed oophorectomies on Pten/
mice. Although there was a reduction in the number
and severity of hyperplastic lesions, the endometrial
phenotype persisted, suggesting that Pten mutation,
independent of estrogen, can initiate the develop-
ment of complex atypical hyperplasia. To recapitulate
the situation in women with unopposed estrogen, we
implanted 17-estradiol pellets in adult female Pten
heterozygous mice, resulting in increased carcinoma
incidence. Because studies have shown that estrogen
largely acts on the endometrium via estrogen receptor
ER, we generated Pten/ER/ mice. Strikingly,
88.9% of Pten/ER/mice developed endometrial
hyperplasia/carcinoma. Furthermore, Pten/ER/
mice showed a higher incidence of in situ and invasive
carcinoma, suggesting that endometrial tumorigenesis can
progress in the absenceof ER. Thus, the relationbetween
Pten alterations and estrogen signaling in the develop-
ment of endometrial carcinoma is complex; the results
2536presented herein have important implications for the
treatment of endometrial hyperplasia and carcinoma in
women. (Am J Pathol 2012, 180:2536–2547; http://dx.doi.
org/10.1016/j.ajpath.2012.03.006)
Endometrial cancer is the most common malignancy of
the female genital tract, and, like most cancers, it is a
complex disease comprising a number of different types
of carcinoma. Clinicopathologic, epidemiologic, and ge-
netic studies have supported a dualistic model of endo-
metrial carcinoma categorized as type I and type II. Type
I carcinoma is the most common, and, although there are
a number of different histologic subtypes, it is usually of
endometrioid histology. Previous studies have shown that
women with uterine endometrioid carcinoma (UEC) often
have increased circulating levels of estrogen and low
levels of progesterone, a situation that results in unop-
posed estrogen stimulation of the endometrium. Further-
more, UEC is usually preceded by complex atypical hyper-
plasia (CAH), which is also thought to be a result of
unopposed estrogen stimulation. Conversely, type II carci-
noma is not associated with unopposed estrogen stimula-
tion, arises in postmenopausal women, and is predomi-
nately of serous histology.1 It has been found that the most
common genetic alteration in UEC is mutation of the
phosphatase and tensin homologue (PTEN) tumor sup-
pressor gene, an alteration that is uncommon in uterine
serous carcinoma.2,3 PTEN mutations have also been
identified in CAH at approximately the same frequency as
in UEC.4,5 Thus, both aberrant PTEN function and unop-
posed estrogen stimulation are thought to play a role in
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between signaling pathways downstream of estrogen
and PTEN. However, little is known about the connection
between estrogen and PTEN signaling in the develop-
ment of endometrial hyperplasia and UEC.
It is currently thought that the effects of estrogen on the
endometrium are mediated primarily via the estrogen re-
ceptor ER.6 ER is a member of a superfamily of nuclear
receptors that act as transcription factors through estro-
gen-independent and estrogen-dependent activation do-
mains.7 Although the endometrial epithelium expresses
ER,8 studies have suggested that the mitogenic effects
of estrogen on the epithelium occur through its interaction
with ER in the endometrial stromal cells.9–11 This leads
to elaboration of growth factors from the stromal cells that
stimulate the epithelium by binding the cognate recep-
tors expressed on the surface of the epithelial cells.12
Growth factors, for example, insulin-like growth factor
and epidermal growth factor, are known to regulate a
diverse number of cellular processes, including cell pro-
liferation, differentiation, motility, and invasion.
PTEN functions primarily as a lipid phosphatase to
regulate the phosphatidyl inositol kinase (PI3K)/AKT
pathway.13 The PI3K/AKT pathway is activated by growth
factors, such as those elicited by the endometrial stromal
cells in response to estrogen.1 This results in the phos-
phorylation of phosphatidylinositol-4,5-phosphate (PIP2)
to generate phosphatidlyinositol-3,4,5-phosphate (PIP3),
previously reported to occur in uterine tissue in response
to estrogen and involving ER.14 Increased levels of PIP3
lead to phosphorylation of AKT, which in turn leads to the
phosphorylation of a large number of proteins that regu-
late cell proliferation, survival, and growth. One of the
actions of PTEN is to dephosphorylate PIP3 to PIP2; thus,
loss of PTEN function results in unchecked activation of
the pathway, leading to increased levels of phosphory-
lated AKT.15 Several in vitro and in vivo studies have
suggested cross talk between PI3K/AKT and estrogen
signaling. ER can bind to the regulatory subunit of PI3K
in the absence or presence of estradiol in epithelial cells
and subsequently activate PI3K/AKT2.16,17 By contrast,
PI3K and AKT can phosphorylate and activate ER in the
absence of estrogen, resulting in its increased ability to
activate the transcription of several target genes.18,19 These
findings suggest that loss of PTEN may function, at least in
part, through activation of ER. In addition, nongenomic
actions of estrogen via a surface receptor have been well
documented,20–22 and this may be another mechanism by
which PTEN and estrogen signaling intersect.
Rodent models have been invaluable to the study of
estrogen’s role in endometrial tumorigenesis. Treatment
of certain mouse strains with diethylstilbestrol (DES) in
the neonatal period results in the development of endo-
metrial carcinoma with histologic features similar to
UEC.23 It has been shown that 100% of Pten/ female
mice develop complex atypical hyperplasia with 20%
developing endometrial carcinoma by 1 year of age.24
Thus, in mice, as in humans, excess estrogen and alter-
ations of Pten appear to be causative factors in the de-
velopment of endometrial hyperplasia and carcinoma. To
better understand the relation of Pten and estrogen/es-trogen receptor in the development of endometrial hyper-
plasia and carcinoma, we used genetically engineered
mouse models with alterations in Pten and ER.
Materials and Methods
Generation of Mouse Strains
Pten/ mice in a mixed C57BL6/129SvJ (B6/129) back-
ground have been described previously.24 To generate
Pten/ genotype in a pure C57BL6 background, the
mice were backcrossed to wild-type C57BL6 females for
10 generations. Pten/ CD-1 mice were generated sim-
ilarly by breeding the Pten/ mixed background mice to
wild-type CD-1 females. ER heterozygous mice, on a
C57BL6 background, were generated at the National Insti-
tutes of Environmental Health Sciences (Research Triangle
Park, NC) under an approved animal study protocol.6 The
Pten/ mixed strain mice were crossed with ER/ mice
to generate Pten/;ER/ mice and the appropriate litter-
mate controls. Animals were genotyped with the use of multi-
plex PCR on genomic DNA prepared from tail samples.6,24
Treatment of Mice with Hormones
To determine the role of estrogen in the development of
endometrial neoplasia, nine virgin Pten/ and wild-type
B6/129 female mice underwent oophorectomy at 3 weeks
of age. At 32 weeks after oophorectomy, the mice were
euthanized, and uteri were harvested for further analysis.
For investigating the effect of excess estrogen, we used
two approaches. For approach 1, we followed an estab-
lished protocol of treating neonatal mice with DES.23
Pten/ mice in the mixed background were treated with
DES (2 g/day per pup) by subcutaneous injections from
day 1 through day 5 of age. Oil-injected animals served as
controls. The animals were sacrificed 24 and 32 weeks after
treatment. The uterine weights were measured and were
submitted for histochemical analysis.
For approach 2, to more closely simulate the situation
of estrogen exposure in women with endometrial carci-
noma, we treated CD-1 Pten/ and wild-type females
with time-release estrogen pellets. Mice underwent
oophorectomy at 12 weeks of age, allowing the uteri to
become fully mature, and the pellets were implanted
immediately after oophorectomy. Seven CD-1 Pten/
mice were implanted subcutaneously once with 90-day
time-release pellets that contained 0.72 mg of 17-estra-
diol (Innovative Research of America, Sarasota, FL) ac-
cording to the manufacturer’s instruction. CD-1 Pten/
(n  7) mice implanted with placebo pellets (Innovative
Research of America) at the time of oophorectomy
served as controls. In addition, 11 CD-1 Pten/ mice
were also implanted with estrogen pellets. Furthermore,
CD-1 Pten/ mice (n  5) were treated with estrogen
pellets twice, once at 12 weeks (immediately after oopho-
rectomy) and the second time after another 12 weeks.
CD-1 Pten/ mice (n  5) treated with estrogen pellets
twice and CD-1 Pten/ mice (n  5) treated with pla-
cebo pellets twice were used as control animals. The
pellets resulted in serum levels of 200 to 250 pg/mL, which
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lating levels. The animals were sacrificed at indicated times
after treatment, and their uteri were harvested.
IHC Analysis
The uteri harvested after treatment from all animals were
processed for H&E staining as well as immunohistochemi-
cal (IHC) analysis. Tissues were formalin-fixed, dehydrated
through an alcohol series, and subsequently embedded in
paraffin. Five-micron sections were stained with H&E. For
IHC, after deparaffinization and hydration through alcohol
grades, slides were subjected to antigen retrieval by boiling
in 10 mmol/L sodium citrate. Antibodies used were anti-
Ki-67 (RM-9106; Lab Vision, Fremont, CA), anti-phospho-
GSK3 S9 (9323; Cell Signaling, Beverly, MA), anti-ER
(SC-542; Santa Cruz Biotechnologies, Santa Cruz, CA),
anti-cyclin D1 (RM-9104; Lab Vision, Fremont, CA). IHC
staining was performed with Elite Vectastain ABC Kit (Vec-
tor Laboratories, Burlingame, CA) according to the manu-
facturer’s instructions. Progesterone receptor (PR) IHC was
performed with the Mouse-on-Mouse (M.O.M.) staining kit
(Vector Laboratories, Burlingame, CA) according to the man-
ufacturer’s instructions. Anti-PR antibody (Immunotech, Mar-
seille, France) was used at 1:50 dilution for 45 minutes at
room temperature.
The number of positive epithelial nuclei for Ki-67was
counted per 1000 nuclei and expressed as percentage
values. Scoring of cyclin D1, p-GSK3, and ER and PR
Figure 1. H&E stained sections of Pten/ mice (A), Pten/ mice (B),
Pten/ mice that had undergone oophorectomy (Ovx) (C), and Pten/
mice that had undergone oophorectomy (D). CAH develops in the absence
of estrogen. Original magnification, 20.
Table 1. Endometrial Lesions in Mice That Have Undergone Oo
Age
(weeks) n
No. (%) of mice
with lesions
Pten/ 32 4 0
Pten/;Ovx 32 9 0
Pten/ 32 9 9 (100)
Pten/;Ovx 32 9 8 (90)*P  0.03, difference was statistically significant.
NA, not applicable; Ovx, oophorectomy.IHC were done to quantify the expression in lesions and
normal epithelium. The localization was determined to be
either nuclear or cytoplasmic. First, staining intensities were
ranked from 1 to 4, corresponding to increasing intensity
with 1 being the least and 4 the strongest. Then the per-
centage of positive cells were estimated by scoring at least
five fields at magnification 100 and ranked from 0 to 4
(0 0%, 1 1% to 25%, 2 26% to 50%, 3 51% to 75%,
and 4  74% to 100%). Final scores were calculated by
multiplying intensity rank numbers with the percentage of
rank numbers and were verified in a single-blinded fashion
by two pathologists (L.H.E. and J.S.Y.C.).
Cell Culture
Parental and PTEN-deleted Hec1A cells were obtained
from the laboratory of Dr. Todd Waldman at the Lombardi
Comprehensive Cancer Center of Georgetown University
(Washington, DC). Cells were maintained in McCoy’s 5A
medium supplemented with 10% charcoal-stripped fetal
bovine serum. Cell proliferation was measured with the
XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophe-
nyl)5-[(phenylamino)-carbonyl]-2H-tetrazolium inner
salt) assay. For XTT assays, 4000 cells were plated in
96-well plates, and the medium was changed to phenol
red-free Dulbecco’s modified Eagle’s medium/F12 sup-
plemented with 15 mmol/L HEPES and either low (1%) or
high (10%) charcoal-stripped fetal bovine serum the next
day. To determine proliferation, XTT solution was added
to wells for each time point, and absorbance was mea-
sured at 492 nm with 595 nm as the reference wavelength
every alternate day for 12 days. For the rest of the wells,
medium was changed every other day. Wells with media
only were used as controls. The absorbance values were
converted to percentage of cell growth with respect to
values on day 1. For effect of serum starvation and re-
stimulation, cells were plated in 6-well dishes in McCoy’s
5A medium at 50% to 60% confluence and changed to
serum-free and phenol red-free McCoy’s 5A medium the
next day. The cells were serum starved for 24 hours,
restimulated with 10% serum for indicated time periods,
and harvested for immunoblot analysis.
Immunoblot Analysis
For immunoblot analysis, cells stimulated with either 1%
or 10% serum for indicated time points were lysed in 250
L/well of a 6-well dish in ice-cold 1 radioimmunopre-
cipitation assay buffer with protease and phosphatase
tomy
of lesions per mouse
(mean  SD)
Size of lesion
(mm2)
Range of size
(mm2)
NA NA NA
NA NA NA
18.56  8.57* 0.22  0.12 0.040.75
8.20  10.27* 0.13  0.13 0.010.96phorec
No.
Tumorigenesis in Pten/ Mice 2539
AJP June 2012, Vol. 180, No. 6inhibitors. Cells were passed through a 27-gauge needle
and clarified by centrifugation at 13,000 rpm for 15 min-
utes at 4°C. All manipulations were performed on ice.
Lysates were resolved on 10% SDS-PAGE, transferred to
polyvinylidene difluoride membrane, and blocked in 5%
nonfat dried milk dissolved in 1 Tris-buffered saline with
0.1% Tween-20 (TBS-T). Membranes were probed with
anti-Pten (9559), anti-phospho-Akt S473 (9271), anti-Akt
(9272), anti-phospho-Erk1/2 (9101), anti-Erk (4695; from
Cell Signaling), anti-cyclin D1 (RM-9104; Lab Vision),
Figure 2. Ki-67 immunostaining on uterine sections of intact Pten/ mice
(A), Pten/ mice that had undergone oophorectomy (Ovx) (B), intact
Pten/ mice (C), and Pten/ mice that undergone oophorectomy (D).
Original magnification, 40. (E) Quantitation of Ki-67-positive cells. Oopho-
rectomy reduced Ki-67-positive cells in the normal epithelium of Pten/
mice. Statistical analysis was performed with the unpaired t-test. *P values
Table 2. Endometrial Lesions in DES-treated Mice
Genotype
Age
(weeks) Treatment n
No.(%) of mic
with lesions
/ 24 DES 11 8 (73)
/ 24 Oil 9 8 (88.9)
/ 32 DES 10 8 (80)
/ 32 Oil 9 9 (100)
/ 24 DES 9 3 (33)
/ 32 DES 11 4 (36)
*P  0.0072, difference was statistically significant.ranging between 0.01 and 0.05 were considered significant; ***P values 
0.001 were considered highly significant.anti-cyclin D3 (SC-182; Santa Cruz Biotechnologies), and
anti-Actin (A5060; Sigma-Aldrich, St. Louis, MO) antibod-
ies. All antibodies were used at a dilution of 1:1000, and
membranes were incubated overnight at 4°C with pri-
mary antibody, washed liberally at room temperature in
TBS-T, and incubated for 1 hour with horseradish perox-
idase-conjugated secondary antibody. After liberal wash-
ing in TBS-T, blots were incubated in Western Lightning
Plus ECL reagent (PerkinElmer, Waltham, MA) and visu-
alized by exposure to electrochemiluminescence film
(Eastman Kodak Co., Rochester, NY).
Statistical Analysis
IHC scores were analyzed with the nonparametric Mann–
Whitney test with P  0.05. The percentage of positive
Ki-67 cells, immunoblot quantitations, and data in the tables
were analyzed with unpaired t-test (two-tailed) with P 
0.05. All analyses were performed with GraphPad Prism
version 5.0 for Mac (GraphPad Software, San Diego, CA).
Results
Development of CAH in Pten/ Mice Is
Estrogen Independent
We first explored whether lack of Pten, excess estrogen,
or both are initiating events for the development of atyp-
ical hyperplasia. Immature (3-week-old) Pten/ and
wild-type mice on the B6/129 background underwent
oophorectomy and were sacrificed at 32 weeks of age,
the age at which 100% of the Pten/ females develop
endometrial hyperplasia.24 All of the mice that had under-
gone oophorectomy exhibited an 75% reduction in uter-
ine weights, as expected because of the absence of estro-
gen. CAH did not develop in wild-type mice that had
undergone oophorectomy or intact wild-typemice (Figure 1, A
and C). Histologic analysis found the presence of CAH in
all (9 of 9) intact Pten/ uteri (Figure 1B). Interestingly, 8
of 9 Pten/ mice that had undergone oophorectomy
also developed CAH (Figure 1D). Although the lesions
were qualitatively similar, the size and number of lesions
were smaller than those in the intact mice. The results have
been summarized in Table 1. These observations suggest
that Pten mutation, in the absence of estrogen, is sufficient
for development of CAH as shown previously.25
In addition, we treated neonatal mice with DES accord-
o. of lesions per mouse
(mean  SD)
Size of lesion
(mm2)
Range of size
(mm2)
2.45  2.77 0.11  0.08 0.040.3
9.78  5.91 0.19  0.16 0.040.64
6.70  7.06* 0.14  0.12 0.030.48
18.56  8.57* 0.22  0.12 0.040.75
1.22  1.99 0.03  0.01 0.020.04
1.18  1.83 0.11  0.14 0.040.48e Ning to established protocols and sacrificed the mice at 24
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ajp.amjpathol.org). The mice treated with DES showed no
significant difference in the uterine weights than mice
Figure 3. Cyclin D1 immunostaining of intact Pten/ mice (A), Pten/
mice that had undergone oophorectomy (Ovx) (B), intact Pten/ mice (C),
and Pten/ mice that had undergone oophorectomy (D). Original magni-
fication, 20. (E) Quantitation of cyclin D1-positive cells. (F) Loss of Pten
reduced cyclin D1 levels in CAH lesions compared with the normal epithe-
lium. Statistical analysis was performed with the Mann–Whitney test. *P
values between 0.01 and 0.05 were considered significant; **P values be-
tween 0.001 and 0.01 were considered very significant.treated with oil. Of the DES-treated Pten/ mice, only33% to 36% developed mild endometrial hyperplasia
(simple hyperplasia). By contrast, all Pten/ mice
treated with oil alone or DES developed CAH (Table 2).
Interestingly, Pten/ mice treated with DES and sacri-
ficed after 32 weeks showed fewer foci of CAH than did
Pten/ mice treated with oil alone. Similar to previous
reports26 we also observed marked fibrosis of the endo-
metrial stroma in DES-treated mice (see Supplemental
Figure S1 at http://ajp.amjpathol.org).
We next determined proliferation indices of uterine
epithelia in the Pten/ mice that had undergone oopho-
rectomy, intact Pten/ mice, and wild-type mice. Ki-67
immunostaining was used as a marker for proliferation,
and positive cells were expressed as a percentage of the
total counted in the normal epithelium and in the CAH.
Oophorectomy significantly reduced the Ki-67-positive
cells in the normal epithelium of Pten/ (Figure 2, A and
B) and Pten/ (Figure 2, C and D) mice. These obser-
vations suggest that lack of estrogen has a similar effect on
normal epithelium irrespective of Pten haploinsufficiency.
The CAH in the intact mice also had significantly more
Ki-67-positive cells than the mice that had undergone oo-
phorectomy (Figure 2, C–E). These findings provide a likely
mechanism for the greater number and increased size of
the CAH foci seen in the intact Pten/ mice.
We also performed immunostaining on the sections
using antibodies to cyclin D1 (Figure 3). Cyclin D1 was
localized to the nucleus in luminal and glandular epithe-
lia, as well as CAH. The slides were scored for staining
intensities as previously described. Overall, there was no
significant difference between cyclin D1-positive cells in
the normal epithelium of Pten/ uteri as compared to
Pten/ mice (Figure 3, A, C, and E). Absence of estro-
Figure 4. p-GSK3(S9) immunostaining in CAH of intact Pten/ mice (A)
and Pten/ mice that had undergone oophorectomy (B). Original magnifi-
cation, 20. Phosphorylation at Ser 9 was significantly up-regulated in the
mice that had undergone oophorectomy (C). Statistical analysis was per-
formed with the Mann–Whitney test. **P  0.005.
were n
Tumorigenesis in Pten/ Mice 2541
AJP June 2012, Vol. 180, No. 6gen (oophorectomy) significantly reduced cyclin D1-pos-
itive cells in the normal epithelium of Pten/ and Pten/
mice (Figure 3, B, D, and E). In intact Pten/mice, cyclin
D1-positive cells in CAH were significantly reduced com-
pared with the normal epithelium (Figure 3, E and F),
showing down-regulation of cyclin D1 in association with
Pten loss in the setting of physiological estrogen levels.
However, in the absence of estrogen, no difference was
observed in the levels of cyclin D1 between CAH and
normal epithelium. In addition, cyclin D1-positive cells in
CAH of Pten/ mice or Pten/ mice that had under-
gone oophorectomy (Figure 3F) did not differ signifi-
cantly, despite the differences in proliferative indices as
measured by Ki-67 staining. The proliferative response to
estrogen in the normal luminal and glandular epithelium
likely involves cyclin D1 in contrast to CAH in which cyclin
D1 is down-regulated in the presence or absence of
estrogen. This suggests that Pten loss is associated with
a decrease in cyclin D1 levels.
Inactivation of GSK3 Is an Estrogen-Independent
Downstream Event in the Pten Pathway
Numerous studies have shown that Pten exerts its tumor
suppressive function through a variety of mechanisms.
The most common mechanism is preventing activation of
Akt by inhibiting phosphorylation on Ser473. In the endo-
metrium, all CAH display the characteristic membrane
staining of p-Akt, further supporting activation of Akt to be
a consistent signaling event in endometrial tumorigenesis
downstream of Pten loss.24 GSK3 is considered a criti-
cal downstream element of the PI3K/Akt pathway. Phos-
pho-Akt inhibits GSK3 action by phosphorylating Ser9,
leading to progression of cells into S phase.27–31 We
therefore investigated the expression of p-GSK3 in CAH
by immunostaining (Figure 4). Approximately 90% of
CAHs in Pten/ mice that had undergone oophorec-
tomy (Figure 4B) showed increased expression of phos-
phorylated GSK3 compared with CAH in the intact
Pten/ mice (Figure 4A), indicating that GSK3 inacti-
vation, initiated by Pten loss, occurs most robustly in the
absence of estrogen when cyclin D1 levels are down
(Mann–Whitney test, P  0.005; Figure 4C). Despite in-
Table 3. Endometrial Lesions in Estradiol-Treated Pten Heterozy
Genotype
Treatment
(weeks) n
No. (%) of mice
with disease
No. (%
with
Pten/(E) 24 5 5/5 (100)
Pten/(P) 24 5 5/5 (100)
Wild type (E) 24 5* 0
Pten/(E) 12 7 7/7 (100)†
Pten/(P) 12 7 7/7 (100)
Wild type (E) 12 6* 0
*Mice had dilated complex hyperplasia without atypia.
†One mouse showed hyperplasia without atypia.
‡P  0.05, difference was not statistically significant.
§P  0.05, difference was not statistically significant. These numbers
E, estradiol pellets; P, placebo pellets.creased levels of p-GSK3, proliferation in CAH ofPten/ mice that had undergone oophorectomy was
reduced compared with intact mice.
Prolonged Estrogen Exposure in Pten/ Mice
Accelerates Progression to Invasion
To avoid the use of mixed background B6-129 mice for
studying hormonal effects, we generated congenic
C57BL6 Pten/ mice by back-crossing the mixed B6-
129 Pten/ mice with C57BL6 mice for 10 generations
(N10). The N10 generation, however, completely lost the
endometrial phenotype (see Supplemental Figure S2, A
and B, at http://ajp.amjpathol.org), which was restored in
the F1 hybrids generated by the cross between Pten/
N10 C57BL6 and wild-type 129SvJ mice. The reason for
loss of phenotype is unknown, but, as this experiment
definitely found, it is due to strain differences. Therefore,
we generated Pten/ mice in the CD-1 background
because this outbred strain had been used to study the
effect of neonatal exposure to DES. In this strain, neonatal
DES treatment resulted in endometrial adenocarcinomas
in 90% of the mice by 18 months of age.23,32 CD-1
Pten/ mice develop CAH similar to the mixed C57BL6/
129SvJ strain, both qualitatively and quantitatively. Adult
CD-1 Pten/ females that had undergone oophorec-
tomy were implanted with either estrogen pellets or pla-
cebos once or twice as described in Materials and Meth-
ods and were sacrificed after 12 or 24 weeks of estradiol
exposure.
As expected, only the Pten/mice developed CAH or
carcinoma (Table 3 and Figure 5). Wild-type mice, even
those treated with estrogen for 24 weeks, developed
dilated complex hyperplasia without cytologic atypia
(Figure 5A). The Pten/ mice, treated with placebo pel-
lets (Figure 5B) or estrogen pellets for 12 weeks (Figure
5C), developed CAH with no significant difference be-
tween the number of lesions or the size (Table 3). How-
ever, three of four Pten/ mice (75%) treated with es-
tradiol for 24 weeks (Figure 5D) developed myoinvasive
carcinomas, whereas the placebo controls for this group
developed only CAH. Of note, the number of lesions in
the Pten/ mice did not differ significantly between those
ice That Had Undergone Oophorectomy
ice
Mice
with
invasion
No. of CAH
per mouse
(mean  SD)
Size (mm2)
of CAH
(mean  SD)
Range of
size
(mm2)
3 19.8  3.86‡ 0.20  0.17 0.04–1.2
0 24.4  9.29‡ 0.14  0.11 0.04–0.8
0
0 6.86  4.30§ 0.11  0.09 0.04–0.25
0 8.4  5.27§ 0.12  0.09 0.04–0.4
0
ot compared with those in ‡.gous M
) of m
CAH
5
5
0
6
7
0treated with estradiol for 24 weeks and the corresponding
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supraphysiological levels of estrogen increased the inci-
dence of invasive endometrial carcinoma in the back-
ground of Pten heterozygosity. Of note, we have never
observed carcinoma at 36 weeks of age in intact Pten/
mice not treated with estrogen.
Uterine sections of CD-1 Pten/ mice were further
analyzed for expression of ER and p-GSK3 by IHC. In
this mouse model as well, we observed increased phos-
phorylation of GSK3 in CAH of the placebo-treated
group compared with the hormone-treated animals
(Mann–Whitney test, P  0.016; data not shown). Anal-
ysis of ER IHC found that ER expression was pre-
dominantly nuclear. When CAH arising in the placebo-
treated animals (Figure 5E) was compared with the
Figure 5. H&E staining of uteri of CD-1 Pten/ mice that had undergone
oophorectomy (A) treated with estradiol pellets for 24 weeks. Pten/
mice (B) treated with placebo pellets for 24 weeks, estradiol pellets for 12
weeks (C) and 24 weeks (D). Prolonged and excess estradiol exposure
increased the incidence of invasive carcinoma (arrows in D). E, estradiol;
P, placebo pellets. ER immunostaining of Pten/ mice treated with
placebo pellets (E) or estradiol pellets for 24 weeks (F). Quantitation of
nuclear ER IHC (G). Invasive carcinoma was associated with reduced
nuclear ER (Mann–Whitney test, *P  0.02), as seen in the insets.
Original magnification: 20 (A–F)l 60 (insets of E and F).carcinomas in the estradiol-treated animals (Figure5F), the nuclear ER expression was significantly re-
duced in the carcinomas (Figure 5G). Treatment with
estradiol for 24 weeks did not significantly affect the
expression of ER in the normal epithelium compared
with the placebo group (Figure 5G).
Endometrial Tumorigenesis in Pten/ Mice
Occurs in the Absence of ER
ER is the predominant estrogen receptor in the uterus,
substantiated by the phenotypes of the ER versus ER
knockout mice.8 Therefore, to dissect the role of ER in
endometrial tumorigenesis, we crossed the Pten/ mice
in the B6-129 mixed background to the ER/ mice
(C57/BL6 background) to generate Pten/;ER/
mice. Wild-type (Pten/;ER/) uteri were histologi-
cally normal (Figure 6A). At 32 weeks (the age at which
100% of Pten/ mice develop CAH), the uteri of the
Pten/;ER/ (Figure 6B) and Pten/;ER/ (Figure
6D) mice were hypoplastic, as would be expected be-
cause of the absence of ER. Despite being hypoplastic,
uteri of 8 (of 9) Pten/;ER/ mice had CAH and/or
carcinoma (Figure 6D). Further, 4 of the 8 mice with
lesions exhibited either in situ carcinoma or carcinoma
with myometrial invasion (Table 4). In contrast, all of the
age-matched Pten/;ER/ (Figure 6C) and Pten/;
ER/mice developed only CAH. Interestingly, as in the
CD-1 mice, the incidence and size of the CAH foci in
Pten/;ER/ and Pten/;ER/ mice did not differ
significantly (Table 4), but the incidence of carcinoma
was significantly increased only in the Pten/;ER/
mice.
Next, we performed Ki-67 immunostaining on uterine
sections of mice of all genotypes (Figure 7, A–D), and the
percentage of positive Ki-67 cells in CAH and/or carci-
noma and normal epithelium were determined (Figure
8A). As expected, the normal epithelium in Pten/;
ER/ (Figure 7B) and Pten/;ER/ (Figure 7D)
mice showed reduced proliferation compared with the
Figure 6. H&E stained sections of uteri in Pten/;ER/ (A), Pten/;
ER/ (B), Pten/;ER/ (C), and Pten/;ER/ (D) mice. Carcinoma
develops in the absence of ER and invades into the myometrium. Original
magnification, 20.
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7C) genotypes. The CAH and carcinoma in the Pten/;
ER/ mice (7.2  4.6) had reduced Ki-67 staining
compared with the CAH in Pten/;ER/ (46.25  9.6)
or Pten/;ER/ (38  7.2) mice (Figure 8A).
Expression of cyclin D1 was analyzed by immunostain-
ing (Figure 7, E–H), and the slides were scored for stain-
ing intensities (Figure 8B). Loss of ER reduced the num-
Figure 7. Immunostaining with Ki-67 (A–D) and cyclin D1 (E–H) on uteri
from Pten/;ER/ (A and E), Pten/;ER/ (B and F), Pten/;
ER/ (C and G), and Pten/;ER/ (D and H) mice. Invasive carcino-
/ /
Table 4. Endometrial Lesions in Pten/ER/ Mice and Litterm
Genotype
Age
(weeks) n
Mice with
lesions
Mice
in si
Pten/ER/ 32 2 0
Pten/ER/ 32 3 0
Pten/ER/ 32 10 10/10
Pten/ER/ 32 7 7/7
Pten/ER/ 32 9 8/9 2
*P  0.104, difference was not statistically significant.mas in the Pten ;ER mice exhibit reduced number of Ki-67-positive
cells but increased staining of cyclin D1. Original magnification, 20.ber of cyclin D1-positive cells in the normal epithelium in
both the Pten/ and Pten/ uteri (Figure 7, F and H)
compared with the wild-type mice (Figure 7E). CAH in
Pten/;ER/ (Figure 7G) exhibited reduced cyclin
D1-positive cells compared with that in the normal epi-
Figure 8. Quantitation of Ki-67 (A) and Cyclin D1 (B) immunostaining
depicted in Figure 7. Statistical analysis for that percentage of positive Ki-67
cells was performed with the unpaired t-test. *P values ranging between 0.01
and 0.05 were considered significant; ***P values  0.001 were considered
highly significant. For cyclin D1, Mann–Whitney test was used. *P values
Mice with
invasion
Lesions per mouse
(mean  SD)
Size of lesion
(mm2)
0
0
0 18.56  8.57 0.22  0.12*
0 5.5  0.71 0.13  0.08*
2/8 9.57  6.78 0.51  0.84ates
with
tu CA
0
0
0
0
/8ranging between 0.01 and 0.05 were considered significant; **P values rang-
ing between 0.001 and 0.01 were considered very significant.
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mice that had undergone oophorectomy, supporting the
notion that Pten loss is associated with down-regulation
of cyclin D1. Pten/;ER/ mice (Figure 7H) exhibited
a different pattern. The normal epithelium had reduced
levels of cyclin D1-positive cells compared with Pten/;
ER/ and Pten/;ER/ mice (Figure 8B). However,
paradoxically the invasive carcinomas expressed more
cyclin D1-positive cells compared with CAH in Pten/;
ER/ and Pten/;ER/mice despite reduced Ki-67
staining (Figure 8B).
We analyzed the expression of progesterone receptor
in the uteri of Pten/;ER/ mice by IHC (see Supple-
mental Figure S3, A and B, at http://ajp.amjpathol.org). PR
expression was predominantly nuclear in the epithelium
and stroma. CAH and carcinomas were also positive for
PR. We did not observe significant differences in the
expression of PR between the normal epithelium and
CAH or between CAH and invasive carcinoma in all of the
genotypes. Even the highly invasive lesions observed in
the Pten/;ER/ mice expressed PR at similar levels.
Analysis of Pathways Using Hec1A Cells with
Somatic Deletion of PTEN
To analyze the interaction between estrogen-ER signal-
ing and Pten in vitro, we used the human endometrialcarcinoma cell line Hec1A, which expresses wild-type
PTEN as well as ER (Figure 9). We obtained two iso-
genic clones (clone 16 and clone 22), which differ from
the parental cell line only for genomic deletion of PTEN.
These clones exhibit increased phosphorylation of AKT
(Figure 9A). Surprisingly, cyclin D1 levels in clones 16
and 22 were always reduced compared with the parental
cells under normal cell culture conditions (Figure 9A).
Clones 16 and 22 have similar expression profiles of
p-AKT and cyclin D1; therefore, only clone 16 was used
in subsequent experiments.
As a first step, we compared the growth characteristics
of parental and PTEN-deleted clone 16 with the use of the
XTT assay (Figure 9C). The parental Hec1A cells grew
faster than clone 16 in conditions of high serum. Condi-
tions of low serum did not affect the growth of clone 16
but significantly reduced the growth of the parental cells.
We next analyzed the response of the cell lines to serum
starvation followed by restimulation with 10% fetal bovine
serum by immunoblot analysis of downstream signaling
molecules in the PI3K/Akt/Pten pathway (Figure 9B).
Clone 16 and parental cells differed in their response to
serum addition. In the absence of serum, both cell types
expressed low levels of cyclin D1. Addition of serum
increased the levels of cyclin D1 protein within 15 min-
utes in the parental cells, and they remained high there-
Figure 9. Analysis of parental and PTEN-de-
leted (clones 16 and 22) Hec1A cells by immu-
noblot analysis (A). Deletion of PTEN activated
AKT in clones 16 and 22. Both clones 16 and 22
expressed reduced cyclin D1 levels under nor-
mal growth conditions. Growth of parental cells
was affected by high (10%) or low (1%) serum,
whereas serum had no effect on growth of clone
16 (C). All time points for the proliferation assay
were done in triplicate, and the values represent
results from three independent experiments. Im-
munoblot analysis of PTEN, p-AKT, p-ERK, and
cyclin D1 in whole-cell lysates of serum-starved
cells after adding serum for indicated time peri-
ods (B) and represent the results obtained from
three independent experiments. Addition of 10%
serum increased cyclin D1 levels in the parental
cells by at least threefold to fourfold as early as 30
minutes (D).after (Figure 9D). However, in clone 16, the addition of
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mained low even 24 hours after the addition of serum. No
effect was observed on p-ERK levels in either of the cell
lines. All together, these observations suggest that dele-
tion of PTEN renders the cells unresponsive to serum,
which may be due, at least in part, to constitutive down-
regulation of cyclin D1. In addition, the reduced cyclin D1
expression correlates with observations made in the
mouse models in which Pten-negative lesions generally
expressed low levels of cyclin D1.
Discussion
Although we have learned a great deal about the relation
of genetics and hormones from epidemiologic and mo-
lecular studies in humans, genetic mouse models allow
direct manipulation of circulating estradiol levels in the
setting of relevant genetic changes. In the present
study, we used genetically engineered mouse models
to investigate the complex interaction between PTEN
and estrogen signaling in the pathogenesis of endo-
metrial carcinoma.
We first showed that CAH developed in 90% of
Pten/ mice that had undergone oophorectomy, al-
though the foci were reduced in number and size com-
pared with controls. These findings suggest that in the
setting of a Pten mutation physiological estrogen levels
may contribute to the development of hyperplasia. Mice
that had undergone oophorectomy also lack progester-
one, which may affect proliferation of endometrial epithe-
lium; however, a previous study of Pten mutant mice
suggested that treatment with progestin did not signifi-
cantly reduce endometrial hyperplasia.25
Given the association of unopposed estrogen stimula-
tion and endometrial carcinoma, we exposed Pten/
mice to exogenous estrogen. The presence of prolonged
excess estradiol resulted in a significant increase in in-
vasive carcinoma, despite similar numbers and size of
CAH foci, suggesting that prolonged exposure to high
levels of unopposed estrogen promotes progression of
CAH to carcinoma in the setting of Pten loss. It was
concluded from recent epidemiologic studies that PTEN
mutations were not associated with the development of
endometrial carcinoma.33 Our findings provide further
support for Pten loss as an important cause of endome-
trial hyperplasia with additional factors, including unop-
posed estrogen, promoting the progression of hyperpla-
sia to carcinoma. The mechanisms by which unopposed
estrogen causes this progression are not known at this
time and require further study. However, it is clear that
additional genetic alterations are important. In primary
human tumor tissues, we have previously reported that
PTEN mutations are common in both hyperplasia and
carcinoma, whereas PIK3CAmutations are limited largely
to carcinomas,34 suggesting a role for PI3K activation in
the invasive phenotype. In addition, it is possible that
reduction in ER expression, as seen here in the mouse
model, may play a role in the progression of the disease.
ER and ER are the most well-characterized nuclear
receptors for estrogen. In addition, a significant body ofliterature reports that estrogen signaling occurs via mem-
brane-bound receptors.22,35,36 In the uterus ER is the
predominant receptor as shown by the phenotypes of
ER and ER knockout mice.6,37 In addition, the prolifer-
ative response to growth factors in the uterus is mediated
via the full-length ER.38 Because it had been shown that
p-Akt results in ligand-independent phosphorylation of
ER and that ER can activate the PI3K pathway, we
sought to determine the role of ER in the development of
endometrial carcinoma in a Pten/;ER/ mouse
model. Despite being severely hypoplastic, uteri of
Pten/;ER/ mice exhibited endometrial hyperplasia/
carcinoma. In fact, absence of ER led to an increased
incidence of in situ and invasive carcinoma. When we
analyzed the uteri for the percentage of Ki-67-positive
cells, the invasive carcinomas had a significantly lower
proliferation index than did CAH in the Pten/;ER/
and Pten/;ER/ mice.
Although epithelial cells express estrogen receptor, it is
believed that estrogen-induced epithelial proliferation is
driven by soluble paracrine factors produced by the
stroma. Given the extensive cross talk in vivo between
the stromal and epithelial cells, it is likely that lack of ER in
the stroma might also contribute to endometrial tumorigen-
esis in Pten/;ER/mice. A study that described stroma-
specific deletion of adenomatous polyposis coli tumor sup-
pressor gene in mice led to endometrial cancer.39
Adenomatous polyposis coli deletion affected estrogen
responsiveness of the stroma, which was because of
reduced ER expression. Normal epithelial PR expres-
sion is also down-regulated by estrogen, acting via stro-
mal ER receptors.40 Interestingly, the invasive carcino-
mas in Pten/;ER/ uteri did not exhibit reduced PR
expression, likely because of ER-negative stroma. Al-
though there are differences between stromal-epithelial
interactions in rodent models and humans, potentially
important information can be provided by these mouse
models for subsequent validation in human tissue and cells.
To this end, we plan on generating epithelial cell-specific
Pten/;ER/ mice by breeding PtenloxP/loxP mice with
previously described exon 3-floxed ER knockout
mice.41 In a previous study, ICI treatment to reduce the
levels of ER resulted in a loss of the endometrial hyper-
plasia/carcinoma phenotype.19 That study was one of the
reasons the present genetic approach was undertaken.
There are a number of possible explanations for the dif-
ferent results of the two studies, the most relevant being
that treatment with ICI only reduced the levels of ER but
did not eliminate them entirely. Furthermore, the strains of
mice and the timing of the ER loss are different.
Cyclin D1 is normally up-regulated in estrogen-in-
duced epithelial cell proliferation in the uterus31,42,43 and
is overexpressed in several cancers, including UEC. De-
spite the presence of considerable proliferation, cyclin
D1-positive cells in CAH of intact and oophorectomized
Pten/ uteri were significantly lower than the normal
epithelium. Another intriguing observation was the in-
creased phosphorylation of GSK3 in CAH of Pten/
mice that had undergone oophorectomy. Phosphoryla-
tion at serine 9 by Akt inactivates GSK3, allowing cells to
progress to S phase, resulting in proliferation in response
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bilization of cyclin D1. Estrogen signaling (via membrane-
associated ERs) can also activate the PI3K pathway and
lead to phosphorylation of GSK3. Given that CAH is
negative for Pten expression, our observations suggest
that biallelic inactivation of Pten, in the absence of estro-
gen, activates alternate proliferation pathways in epithe-
lial cells via inactivation of GSK3, which do not involve
cyclin D1. Further support for altered response of cells
because of Pten deletion was provided by the observa-
tion that PTEN-deleted human endometrial carcinoma
cell line Hec1A was insensitive to the presence of serum
for growth characteristics and modulation of cell cycle
proteins compared with the parental cell line. Interest-
ingly, similar to the mouse models presented here, cyclin
D1 expression was significantly reduced in the clone,
possibly causing the refractoriness to serum. However,
invasive carcinomas also had significantly higher cyclin
D1-positive cells, suggesting that, in the progression to
invasive endometrial disease, cyclin D1 may be involved
in other processes besides entry into the G1 phase of the
cell cycle. Given the observation that cyclin D1 is over-
expressed in many other tumor types and that it cannot
induce cellular transformation by itself, several alternate
functions for cyclin D1 other than the classical G0 to G1
transition in the cell cycle have been suggested.46
Among the several functions, its ability to influence tran-
scription by interaction with steroid receptors and the
transcription machinery47,48 might be highly relevant in
the context of endometrial carcinoma.
These studies highlight the complex interaction be-
tween hormones and genetics in the development of
UEC. Importantly, however, the mouse studies have shed
light on some important issues that are encountered in
the treatment of this common cancer in women. For ex-
ample, the results presented herein provide evidence for
the fact that biallelic inactivation of PTEN can result in
CAH in the absence of estrogen. This finding may explain
why women without clinical evidence of unopposed es-
trogen stimulation can develop CAH. Furthermore, we
also show that unopposed estrogen stimulation in the
setting of PTEN mutation may increase the likelihood of
progression to carcinoma. These findings may have clin-
ical ramifications for the treatment of PTEN-deficient en-
dometrial hyperplasia and the treatment of Cowden dis-
ease. Finally, these studies suggest that the loss of ER
may not simply be a consequence of decreasing tumor
differentiation, as is the common interpretation, but
may be a mechanism by which tumors become more
aggressive.
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